These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 15102096)

  • 21. Self-assembling CpG DNA nanoparticles for efficient antigen delivery and immunostimulation.
    Rattanakiat S; Nishikawa M; Takakura Y
    Eur J Pharm Sci; 2012 Sep; 47(2):352-8. PubMed ID: 22771546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides.
    Wilson JT; Keller S; Manganiello MJ; Cheng C; Lee CC; Opara C; Convertine A; Stayton PS
    ACS Nano; 2013 May; 7(5):3912-25. PubMed ID: 23590591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses.
    Newman MJ; Wu JY; Gardner BH; Munroe KJ; Leombruno D; Recchia J; Kensil CR; Coughlin RT
    J Immunol; 1992 Apr; 148(8):2357-62. PubMed ID: 1373166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
    Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
    Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes.
    Li WM; Dragowska WH; Bally MB; Schutze-Redelmeier MP
    Vaccine; 2003 Jul; 21(23):3319-29. PubMed ID: 12804863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concomitant delivery of a CTL-restricted peptide antigen and CpG ODN by PLGA microparticles induces cellular immune response.
    Fischer S; Schlosser E; Mueller M; Csaba N; Merkle HP; Groettrup M; Gander B
    J Drug Target; 2009 Sep; 17(8):652-61. PubMed ID: 19622019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TLR-9 agonist immunostimulatory sequence adjuvants linked to cancer antigens.
    Shirota H; Klinman DM
    Methods Mol Biol; 2014; 1139():337-44. PubMed ID: 24619691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
    Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
    Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of protective CTL responses against the Plasmodium yoelii circumsporozoite protein by immunization with peptides.
    Franke ED; Corradin G; Hoffman SL
    J Immunol; 1997 Oct; 159(7):3424-33. PubMed ID: 9317141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Co-administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG-oligodeoxynucleotide induces potent antitumor immunity.
    Woo SJ; Kim CH; Park MY; Kim HS; Sohn HJ; Park JS; Kim HJ; Oh ST; Kim TG
    Cancer Sci; 2008 May; 99(5):1034-9. PubMed ID: 18294279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction.
    Garbi N; Arnold B; Gordon S; Hämmerling GJ; Ganss R
    J Immunol; 2004 May; 172(10):5861-9. PubMed ID: 15128765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer.
    Lubaroff DM; Karan D; Andrews MP; Acosta A; Abouassaly C; Sharma M; Krieg AM
    Vaccine; 2006 Aug; 24(35-36):6155-62. PubMed ID: 16876291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunostimulatory CpG motifs induce CTL responses to HIV type I oligomeric gp140 envelope protein.
    Rao M; Matyas GR; Vancott TC; Birx DL; Alving CR
    Immunol Cell Biol; 2004 Oct; 82(5):523-30. PubMed ID: 15479438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [CpG oligodeoxynucleotide enhances humoral and cellular immune responses against HBsAg in mice].
    Zhou Z; Chen WS; Yao JL
    Zhonghua Nei Ke Za Zhi; 2003 Sep; 42(9):640-2. PubMed ID: 14514394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.
    Tewary P; Sukumaran B; Saxena S; Madhubala R
    Vaccine; 2004 Aug; 22(23-24):3053-60. PubMed ID: 15297055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.
    Wingender G; Garbi N; Schumak B; Jüngerkes F; Endl E; von Bubnoff D; Steitz J; Striegler J; Moldenhauer G; Tüting T; Heit A; Huster KM; Takikawa O; Akira S; Busch DH; Wagner H; Hämmerling GJ; Knolle PA; Limmer A
    Eur J Immunol; 2006 Jan; 36(1):12-20. PubMed ID: 16323249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of antigen-specific cytotoxic T lymphocytes by immunization with negatively charged soluble antigen through scavenger receptor-mediated delivery.
    Yamasaki Y; Ikenaga T; Otsuki T; Nishikawa M; Takakura Y
    Vaccine; 2007 Jan; 25(1):85-91. PubMed ID: 16956699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topical TLR9 agonists induce more efficient cross-presentation of injected protein antigen than parenteral TLR9 agonists do.
    Najar HM; Dutz JP
    Eur J Immunol; 2007 Aug; 37(8):2242-56. PubMed ID: 17634951
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Artificially synthesized helper/killer-hybrid epitope long peptide (H/K-HELP): preparation and immunological analysis of vaccine efficacy.
    Masuko K; Wakita D; Togashi Y; Kita T; Kitamura H; Nishimura T
    Immunol Lett; 2015 Jan; 163(1):102-12. PubMed ID: 25479286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The synthetic TLR2 agonist BPPcysMPEG leads to efficient cross-priming against co-administered and linked antigens.
    Prajeeth CK; Jirmo AC; Krishnaswamy JK; Ebensen T; Guzman CA; Weiss S; Constabel H; Schmidt RE; Behrens GM
    Eur J Immunol; 2010 May; 40(5):1272-83. PubMed ID: 20213735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.